Pila Pharma AB
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is hea… Read more
Pila Pharma AB (PILA) - Net Assets
Latest net assets as of December 2025: Skr14.78 Million SEK
Based on the latest financial reports, Pila Pharma AB (PILA) has net assets worth Skr14.78 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr16.22 Million) and total liabilities (Skr1.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr14.78 Million |
| % of Total Assets | 91.16% |
| Annual Growth Rate | 59.13% |
| 5-Year Change | -51.2% |
| 10-Year Change | 2190.29% |
| Growth Volatility | 358.68 |
Pila Pharma AB - Net Assets Trend (2015–2025)
This chart illustrates how Pila Pharma AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pila Pharma AB (2015–2025)
The table below shows the annual net assets of Pila Pharma AB from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr14.78 Million | +181.01% |
| 2024-12-31 | Skr5.26 Million | -21.02% |
| 2023-12-31 | Skr6.66 Million | -30.10% |
| 2022-12-31 | Skr9.53 Million | -68.54% |
| 2021-12-31 | Skr30.30 Million | +785.77% |
| 2020-12-31 | Skr3.42 Million | -54.14% |
| 2019-12-31 | Skr7.46 Million | +14.85% |
| 2018-12-31 | Skr6.49 Million | -6.69% |
| 2017-12-31 | Skr6.96 Million | +978.01% |
| 2016-12-31 | Skr645.51K | +355.00% |
| 2015-12-31 | Skr141.87K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pila Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10943987000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.80 Million | 12.17% |
| Other Components | Skr123.33 Million | 834.23% |
| Total Equity | Skr14.78 Million | 100.00% |
Pila Pharma AB Competitors by Market Cap
The table below lists competitors of Pila Pharma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Digistar Corporation Bhd
KLSE:0029
|
$1.85 Million |
|
CopperEx Resources Corporation
V:CUEX
|
$1.85 Million |
|
Amfin Financial Corp
PINK:AFNL
|
$1.85 Million |
|
Highway 50 Gold Corp
PINK:HGGCF
|
$1.85 Million |
|
DONTNOD Entertainment SA
PA:ALDNE
|
$1.85 Million |
|
Interpace Biosciences Inc
OTCQX:IDXG
|
$1.85 Million |
|
Tactical Resources Corp.
PINK:USREF
|
$1.85 Million |
|
MBB (MBB.SG)
STU:MBB
|
$1.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pila Pharma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,261,000 to 14,784,000, a change of 9,523,000 (181.0%).
- Net loss of 16,863,000 reduced equity.
- New share issuances of 28,940,000 increased equity.
- Other factors decreased equity by 2,554,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-16.86 Million | -114.06% |
| Share Issuances | Skr28.94 Million | +195.75% |
| Other Changes | Skr-2.55 Million | -17.28% |
| Total Change | Skr- | 181.01% |
Book Value vs Market Value Analysis
This analysis compares Pila Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 134.87x to 2.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr0.01 | Skr1.22 | x |
| 2016-12-31 | Skr0.04 | Skr1.22 | x |
| 2017-12-31 | Skr0.44 | Skr1.22 | x |
| 2018-12-31 | Skr0.41 | Skr1.22 | x |
| 2019-12-31 | Skr0.47 | Skr1.22 | x |
| 2020-12-31 | Skr0.22 | Skr1.22 | x |
| 2021-12-31 | Skr2.26 | Skr1.22 | x |
| 2022-12-31 | Skr0.55 | Skr1.22 | x |
| 2023-12-31 | Skr0.32 | Skr1.22 | x |
| 2024-12-31 | Skr0.21 | Skr1.22 | x |
| 2025-12-31 | Skr0.43 | Skr1.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pila Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -114.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1496.27%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.10x
- Recent ROE (-114.06%) is above the historical average (-205.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -634.57% | 0.00% | 0.00x | 2.73x | Skr-914.45K |
| 2016 | -230.21% | 0.00% | 0.00x | 2.00x | Skr-1.55 Million |
| 2017 | -68.49% | 0.00% | 0.00x | 1.08x | Skr-5.46 Million |
| 2018 | -86.26% | 0.00% | 0.00x | 1.13x | Skr-6.25 Million |
| 2019 | -116.24% | -2502.34% | 0.04x | 1.06x | Skr-9.41 Million |
| 2020 | -309.46% | 0.00% | 0.00x | 1.57x | Skr-10.93 Million |
| 2021 | -56.80% | -2392.46% | 0.02x | 1.05x | Skr-20.24 Million |
| 2022 | -280.98% | -1423.74% | 0.17x | 1.14x | Skr-27.73 Million |
| 2023 | -149.07% | -678.73% | 0.17x | 1.27x | Skr-10.60 Million |
| 2024 | -213.67% | -1450.45% | 0.12x | 1.18x | Skr-11.77 Million |
| 2025 | -114.06% | -1496.27% | 0.07x | 1.10x | Skr-18.34 Million |
Industry Comparison
This section compares Pila Pharma AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pila Pharma AB (PILA) | Skr14.78 Million | -634.57% | 0.10x | $1.85 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |